- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Windlas Biotech Limited — Important, 10-02-2026: Updates
10-02-2026 | 05:19 pm
10-02-2026 | 05:19 pm
Windlas Biotech's Codeine cough syrup production is temporarily suspended after a Show Cause Notice from drug authorities. This product line contributed Rs. 55.21 Cr to current FY revenue. Only Codeine-based syrups are affected; other production continues normally.
No comments yet. Be the first to comment!